INDP
Indaptus Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$3.09Close
$6.7MMarket cap
$1.13 – $4.0052-week range
Nov 11, 2026Next report
Highlights
Cautions
- Results soon Nov 11, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
23%
1wk
down 2.2%
price change
1mo
up 34.3%
price change
12-month return
up 173%
total, dividends included
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.1×
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 588%
return on equity
Free cash margin
—
-$14.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
11.2%
$0.35 a day · 2×ATR $2.40
RS
—
vs the universe
Trend
—
trend template
Relative volume
—
vs 50-day average
Up/down volume
—
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 405.4% over the year, from 0m to 2m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 13, 2026
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$3.6M | -$7.7M | -$14.9M | -$16.4M | -$15.4M | -$19.8M |
| Net income | -$3.6M | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| Earnings per share | — | -$1.89 | -$1.73 | -$1.84 | -$44.96 | -$21.58 |
| Free cash flow | -$3.3M | -$11.3M | -$13.1M | -$13.4M | -$12.3M | -$14.8M |
| Cash | $1.6M | $39.1M | $9.6M | $13.4M | $5.8M | $8.5M |
| Shareholders' equity | -$237,701 | $35.9M | $24.6M | $12.1M | $3.9M | $3.2M |
| Shares outstanding | 1.94m | 8.26m | 8.40m | 8.40m | 428.80k | 2.17m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 15, 2026 | Quarterly ↗ | Mar 31, 2026 | 45d |
| Mar 17, 2026 | Annual ↗ | Dec 31, 2025 | 76d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 13, 2025 | Annual ↗ | Dec 31, 2024 | 72d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 13, 2024 | Annual ↗ | Dec 31, 2023 | 73d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 20, 2026 | Other events ↗ |
| Sep 30, 2026 | Material agreement ↗ |
| Sep 10, 2026 | Material agreement · Unregistered share sale ↗ |
| Sep 4, 2026 | Director or officer change ↗ |
| Sep 1, 2026 | Material agreement ↗ |
| Aug 13, 2026 | Results · Shareholder vote ↗ |
| Jun 24, 2026 | Material agreement · Unregistered share sale ↗ |
| Jun 5, 2026 | Director or officer change ↗ |
| May 15, 2026 | Results ↗ |
| Apr 23, 2026 | Director or officer change ↗ |
| Apr 3, 2026 | Director or officer change ↗ |
| Mar 24, 2026 | Change of control · Director or officer change ↗ |